Investor Relations

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. We plan to launch our two epilepsy products, Oxtellar XR^TM in the first quarter of 2013 and Trokendi XR^TM after it receives final approval by the FDA, in the third quarter of 2013. We are developing several product candidates in psychiatry to address large market opportunities in attention deficit hyperactivity disorder, or ADHD, including ADHD with impulsive aggression. We intend to market our products in the United States through our own focused sales force targeting specialty physicians, including neurologists and psychiatrists. We believe our diversified and broad portfolio of product candidates provides us with multiple opportunities to achieve our goal of becoming a leading specialty pharmaceutical company focused on CNS diseases.

View all »   Recent Releases

May 20, 2013
Supernus to Present at Two Investor Conferences

May 13, 2013
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results